PM
CDTX

Prosight Management’s Cidara Therapeutics CDTX Stock Holding History

Prosight Management’s Portfolio CDTX Stock Details CDTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-17,948
Closed -$603K – 37
2019
Q2 		$603K Buy
17,948
+6,935
+63% +$288K 0.3% 37
2019
Q1 		$584K Sell
11,013
-1,275
-10% -$69.9K 0.26% 36
2018
Q4 		$578K Sell
12,288
-3,957
-24% -$282K 0.3% 34
2018
Q3 		$1.43M Sell
16,245
-41,690
-72% -$3.68M 0.8% 27
2018
Q2 		$6.03M Sell
57,935
-1,383
-2% -$131K 4.42% 8
2018
Q1 		$4.75M Sell
59,318
-23,076
-28% -$3.15M 2.98% 15
2017
Q4 		$11.2M Buy
+82,394
New +$12.5M 8.24% 3

Other funds holding CDTX

BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $186M AUM 155.23% 1-Year Est. Return
IVM
InterWest Venture Management San Francisco, California $20.6M AUM 48.5% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
AC
Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
ACM
Alethea Capital Management Mercer Island, Washington $241M AUM 112.74% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.81B AUM 83.9% 1-Year Est. Return

Prosight Management's CDTX Position: Q3 2019 in Review

Prosight Management sold out of Cidara Therapeutics (CDTX) in Q3 2019, closing a stake of 17,948 shares — an estimated $603K sold.

Prosight Management first reported a position in CDTX in Q4 2017 and held it in 7 quarters. The position peaked at $11.2M in Q4 2017. 39 funds tracked by Wall St. Rank hold CDTX as of Q3 2019.

  • Prosight Management reported no remaining Cidara Therapeutics position as of Q3 2019 after selling out during the quarter.
  • Prosight Management sold 17,948 Cidara Therapeutics shares in Q3 2019, an estimated $603K.
  • Prosight Management first reported a position in Cidara Therapeutics in Q4 2017 and held it in 7 quarters.
  • Prosight Management's Cidara Therapeutics position peaked at $11.2M in Q4 2017.
  • 39 funds tracked by Wall St. Rank held Cidara Therapeutics as of Q3 2019.

Based on Prosight Management's 13F filing for Q3 2019, filed 14 Nov 2019.